NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $34.00 target price on the stock.

A number of other research firms have also commented on NRXP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, December 16th. Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday. Zacks Research upgraded NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Finally, Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $36.75.

NRx Pharmaceuticals Trading Down 0.8%

NASDAQ NRXP opened at $2.39 on Monday. The firm has a market capitalization of $70.74 million, a PE ratio of -1.02 and a beta of 1.62. The business’s 50-day moving average price is $2.43 and its two-hundred day moving average price is $2.78. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. As a group, analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Ethos Financial Group LLC bought a new position in shares of NRx Pharmaceuticals in the 3rd quarter worth $39,000. One Wealth Management Investment & Advisory Services LLC raised its holdings in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares during the last quarter. Finally, AdvisorShares Investments LLC increased its position in shares of NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after acquiring an additional 78,339 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.